This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

IntegraMed America Presentation At Oppenheimer Healthcare Conference - Transcript

We have a strong value proposition to the physicians and the clinics that we work with, and we surround them with a variety of support services that enable those centers and those clinics to be more successful than they otherwise would be on a standalone basis. So integrated IT systems, very sophisticated patient acquisition programs, care coordination, revenue cycle management. Of course we have capital, which is very important for the capital-intensive nature of these two businesses, and a lot of administrative systems.

So by surrounding these centers with that level of support, what we’re able to accomplish is to grow these small businesses much more quickly than they are able to grow on a standalone basis, because they’re able to leverage off of these investments that we make in supporting their growth.

These are both large addressable and underpenetrated markets. If you take a look at the IVF market as an example, about 7.3 million women, couples, in the United States, do experience infertility, but a very small percentage of those actually access IVF treatment. A little bit greater proportion access infertility treatment, but still there’s a big gap between the number of couples that could benefit from treatment and the number that actually access treatment.

The biggest disconnect there is that it’s not a condition that is universally reimbursed by insurance companies. So there’s a fairly significant financial barrier for couples to access sophisticated treatment. I’m not sure that we’re ever going to see a full penetration of the market, but we do see continued upside growth in the market because it is so underpenetrated.

The vein care market is even more underpenetrated. There’s about 25 million people in the United States who suffer from varicose veins, and only about 1 in 25 are actually accessing treatment in any one year. And the reason for that is that the treatment historically has been very uncomfortable, the surgical procedure.

3 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,683.58 -46.53 -0.26%
S&P 500 2,068.76 -8.02 -0.39%
NASDAQ 4,991.94 -17.2740 -0.34%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs